Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AT 101

Drug Profile

AT 101

Alternative Names: (-)-gossypol; AT-101; Bcl-2/xL inhibitor - 3SBio; R-(-)-gossypol acetic acid

Latest Information Update: 29 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer 3SBio; Ascenta Therapeutics; Ascentage Pharma; Mayo Clinic; National Cancer Institute (USA)
  • Class Antineoplastics; Sesquiterpenes; Small molecules
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Non-small cell lung cancer
  • Phase I/II Multiple myeloma
  • No development reported Solid tumours
  • Discontinued Glioblastoma; Non-Hodgkin's lymphoma; Oesophageal cancer; Prostate cancer; Small cell lung cancer

Most Recent Events

  • 29 Sep 2022 No development reported - Phase-II for Chronic lymphocytic leukaemia in Australia (PO)
  • 29 Sep 2022 No development reported - Phase-II for Chronic lymphocytic leukaemia in China (PO)
  • 15 Sep 2020 Phase-II clinical trials in Chronic lymphocytic leukaemia in Australia (PO) (Ascentage Pharma pipeline, September 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top